Graticule’s global research network provides curated near-real time data for COVID-19 research

  • Health system partners in multiple known COVID-19 hotspots in the US and Europe
    • Deep integrated registries of tested, COVID+, hospitalized, and ICU patients
    • Clinicians expert in treating patients with local standard of care
    • Tools to enable advanced information such as radiology
  • Health Information Technology partners:
    • Large radiology (e.g. Chest CTs and notes) Health Information Exchange available to identify patients in need of hospitalization
    • Mobile monitoring solution including device information such as pulse ox for mild symptomatic and asymptomatic patients
    • Skilled nursing facility EHR system with rapidly growing (45K+) COVID-19 positive cases
    • Patient social network with 1M+ patients with conditions of interest and medication use able to initiate outreach to COVID-19+ patients
    • Free text clinical search engine optimized to mine unstructured radiology and clinical notes for COVID-19 related data (e.g. spirometry)
    • National scale emergency department clinical and administrative information
    • Historical archive data to understand therapy safety for potential drug repositioning
    • Participation in linkage networks, data aggregators, and data exchanges for connecting data across COVID-19 data sets
  • Collection and communication of common requirements from sponsors
    • Defining business requirements for multiple life sciences organizations seeking common data needs
    • CRO collaborations to support novel clinical trials including drug repositioning, basket trials and vaccine development
    • Webinars and blog posts with real world data industry leaders regarding common needs and potential solutions

COVID-19 Subject Matter Expertise and Data Capabilities

Graticule’s expertise in data licensing, enrichment, and curation with these data sets can enable

  • Match making: The Graticule team matches data partners to address specific needs sponsors pose as challenges. Working with your team we define protocol summaries to communicate your needs and offer summary information on available cohorts for feasibility analysis to meet them.
  • Extending data: We offer creative approaches such as outreach through social networks, data linking, and contracting for data access across sites to rapidly extend data availability to answer urgent complex questions.
  • Sponsored curation initiatives for specific studies: We are engaging with our health system partners to extract and curate data required for multiple RWE studies. These will extend the already rich registries at health systems established for patient care.
  • Available imaging data: Graticule offers a collection of de-identified imaging studies (i.e., chest x-ray and CT with lung inflammation) that can be enriched for COVID-19 research and is acquiring relevant new radiology data from January 2020 when the pandemic was first diagnosed in the US.

COVID-19 Real World Data Applications

  • Synthetic control arms and basket trials: Accelerate COVID-19 clinical trials by leveraging standard of care based controls and establish/participate in basket trials with common placebo arms to accelerate trial enrollment and optimize resources during pandemic
  • Clinical trial design: Design of clinical trials to determine populations for accelerated vaccine programs, and criteria for successful end-points for interventional medications within the complex environment of a pandemic with over 900 concurrent trials
  • Repurposing or repositioning: Evaluate safety and effectiveness of existing drugs of interest by tracking clinical outcomes & reported adverse events for both historical cohorts and cohorts with COVID-19 receiving the medication prior to exposure
  • Treatment response: Visibility into complex treatment responses through advanced data such as images and free text notes from patient records
  • Biomarker and AI diagnostic discovery: Review of structured and unstructured data enables predictive models of patient trajectories that can be used for decision support
  • Patient journey mapping: At home applications and telehealth data can provide insight into mild and asymptomatic cases. Medical records and advanced device information from registries provide a map of the journey for higher acuity cases. Background data from historical claims and genetics can provide insights into stratification of risk and journeys.
  • Disease progression: Study patterns in imaging data to review & understand disease progression for prevention and therapeutic intervention.

Resources

Episode 6: Scope of Real-world Data in Drug Repositioning

covid19, Podcasts|

The N3C provides a unique resource for commercial organizations seeking to execute COVID-19 related research. In this podcast Dan Housman interviewed Joy Alamgir from ARI Science, an early adopter from a commercial research group having executed one of the first approved Data Use Requests. The conversation explores their decision to use N3C as a platform to study the real world performance of marketed drugs they have identified for repurposing for COVID-19. Joy provides insight into how his team learned about N3C, alternatives his team considered, the key benefits to his group, and ARI Science's early experience working with the enclave and data sets.[Read more]

Episode 4: Insights from N3C : New RWD Initiative

covid19, Podcasts|

In this podcast, Melissa Haendel, Director at CD2H and Christopher Chute Co-Director at CD2H discuss the key goals of the N3C initiative and its unique value proposition. The podcast provides insights into how this collaborative effort brings together experts with knowledge, skills, and experience to address this urgent public health issue. The podcast outlines the scope, opportunities, and challenges of N3C association with the commercial groups such as pharma & med-devices. It also touches upon the various roadblocks faced by the team in their journey so far. [Read more]

Catalog of RWE COVID-19 Initiatives

Blog post, covid19|

Many organizations have responded to the challenge of the COVID-19 pandemic with a variety of focused and novel Real World Data solutions. We have decided to share our research of COVID-19 RWD initiatives as a public catalog available with active updates as we learn about new efforts. [Read more]